Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.85 |
| ▸ | POLB | P06746 | 2/20 | 0.85 |
| ▸ | CTDSP1 | Q9GZU7 | 4/20 | 0.65 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.61 |
| ▸ | KAT2A | Q92830 | 4/20 | 0.61 |
| ▸ | EP300 | Q09472 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.60 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.60 |
| ▸ | CCR6 | P51684 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.60 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.60 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084943 | 1.00 | MEN1 (0.85) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL4797604 | 0.88 | MEN1 (0.68) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL12934213 | 0.88 | MEN1 (0.68) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL14252589 | 0.88 | MEN1 (0.68) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL4797610 | 0.88 | MEN1 (0.68) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL2084589 | 0.85 | MEN1 (0.64) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL5711322 | 0.85 | MEN1 (0.64) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL2332224 | 0.85 | MEN1 (0.64) | MEN1KMT2APOLBCTDSP1KAT2B | |
| SCHEMBL2083915 | 0.82 | KMT2A (0.82) | MEN1KMT2APOLBCTDSP1TDP1 | |
| SCHEMBL14440259 | 0.82 | KMT2A (0.82) | MEN1KMT2APOLBCTDSP1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885717-B1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX DELBRUECK CENTRUM (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7868185-B2 | Shp-2 inhibitors and pharmaceutical compositions comprising them | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20080194563-A1 | Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1885717-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128909-A1 | SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194563-A1 | Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases | PTPN2, PTPRJ, PTPRS | MEN1 856/4885KMT2A 1268/4885POLB 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.